Critical Contrast: Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND)

Clearmind Medicine (NASDAQ:CMND) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Clearmind Medicine and Relmada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-207.53%	-100.70%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Volatility & Risk

Clearmind Medicine has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Clearmind Medicine and Relmada Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0	0	0	0	0.00
Relmada Therapeutics	1	1	4	1	2.71

Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 90.17%. Given Relmada Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Clearmind Medicine.

Insider and Institutional Ownership

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Clearmind Medicine and Relmada Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86 million	($197.20)	-0.01
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.09)	-5.79

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Summary

Relmada Therapeutics beats Clearmind Medicine on 8 of the 12 factors compared between the two stocks.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.